VCYT: Double-digit revenue growth, new product launches, and raised 2026 guidance highlight strong Q2
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 15% revenue growth and strong profitability, driven by new product launches and expanded clinical evidence. Guidance for 2026 was raised, with revenue expected to grow 14–15% and adjusted EBITDA margin to exceed 26%.Original document: Veracyte, Inc. [VCYT] SEC 8-K Current Report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 15% revenue growth and strong profitability, driven by new product launches and expanded clinical evidence. Guidance for 2026 was raised, with revenue expected to grow 14–15% and adjusted EBITDA margin to exceed 26%.
Original document: Veracyte, Inc. [VCYT] SEC 8-K Current Report — Jul. 30 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.